Comment on

• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

  Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE. Hansson L, et al. Lancet. 1999 Feb 20;353(9153):611-6. doi: 10.1016/s0140-6736(98)05012-0. Lancet. 1999. PMID: 10030325 Clinical Trial.
• Differences between blood-pressure-lowering drugs.

  MacMahon S, Neal B. MacMahon S, et al. Lancet. 2000 Jul 29;356(9227):352-3. doi: 10.1016/S0140-6736(00)02521-6. Lancet. 2000. PMID: 10972362 No abstract available.
• Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.

  Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlöf B, Karlberg BE. Hansson L, et al. Lancet. 2000 Jul 29;356(9227):359-65. doi: 10.1016/s0140-6736(00)02526-5. Lancet. 2000. PMID: 10972367 Clinical Trial.
• Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

  Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Brown MJ, et al. Lancet. 2000 Jul 29;356(9227):366-72. doi: 10.1016/S0140-6736(00)02527-7. Lancet. 2000. PMID: 10972368 Clinical Trial.